# US 2021/0275458 A1 · Tablet formulation comprising a glp-1 peptide and a delivery agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275458 A1
- Document ID: US20210275458A1
- Status: Published application
- Kind: A1
- Application number: 17/320,436
- Filed: 2021-05-14
- Published: 2021-09-09
- Earliest claimed: 2012-06-20
- Assignees: Novo Nordisk A/S
- Applicants: Novo Nordisk A/S
- Inventors: Simon Bjerregaard; Per Sauerberg; Flemming Seier Nielsen; Betty Lomstein Pedersen; Erik Skibsted
- Web page: https://patentgrep.com/patent/US20210275458A1

## CPC

- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2095: {Tabletting processes}
- A61K 38/26: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.

## Claims

### Claim 1

A tablet comprising a granulate comprising:
i) no more than 15% (w/w) GLP-1 peptide, and
ii) at least 50%, 55%, or 60% (w/w) salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC).

### Claim 2 (depends on 1)

A tablet according to claim 1, wherein said peptide comprises a substituent comprising a fatty acid or a fatty diacid, of formula (X)
wherein n is at least 13;
and wherein said peptide optionally comprises one or more 8-amino-3,6-dioxaoctanoic acid (OEG).

### Claim 3 (depends on 1)

A tablet according to claim 1, wherein said GLP-1 peptide is semaglutide.

### Claim 4 (depends on 1)

A tablet according to claim 1, wherein said salt of NAC is monosodium NAC (SNAC), anhydrous SNAC monosodium salt.

### Claim 5 (depends on 1)

A tablet according to claim 1, wherein the amount of said salt of NAC is 50-90% (w/w), 55-85% (w/w), or 70-80% (w/w).

### Claim 6 (depends on 1)

A tablet according to claim 1, wherein said tablet comprises an intragranular and an extragranular part, wherein said extragranular part comprises a lubricant and optionally a filler.

### Claim 7 (depends on 1)

A tablet according to claim 1, wherein said tablet comprises
a) a granulate comprising
i) 1-15% (w/w) GLP-1 peptide,
ii) 55-85% (w/w) salt of NAC, and
iii) 1-20% (w/w) binder;
b) 10-35% (w/w) filler; and
c) 0.5-3% (w/w) lubricant.

### Claim 8 (depends on 1)

A tablet according to claim 1, wherein said tablet does not comprise a superdisintegrant.

### Claim 9 (depends on 1)

A tablet according to claim 1, wherein said tablet is for oral administration.

### Claim 10 (depends on 1)

A tablet according to claim 1, wherein said tablet was prepared by exerting a compression force of at least 5 kN, such as 5-25 kN, at least 10 kN or at least 15 kN, or at least 4 kN/cm2, such as at least 6 kN/cm2 or at least 8 kN/cm2.

### Claim 11 (depends on 1)

A method of treating type 2 diabetes or obesity comprising administering to a subject in need of such treatment a tablet according to claim 1.

### Claim 12

A process for the preparation of a tablet comprising a granulate comprising i) no more than 15% (w/w) GLP-1 peptide, and ii) at least 50% (w/w) salt of NAC, said method further comprising the step of exerting a compression force when punching said tablet of a) at least 5 kN, such as 5-25 kN, at least 10 kN or at least 15 kN, and/or b) at least 4 kN/cm2, such as at least 6 kN/cm2 or at least 8 kN/cm2,
wherein said process optionally comprises a pre-compression step.

### Claim 13 (depends on 1)

A method for controlling porosity of the tablet of claim 1, said method comprising the steps of:
a) determining the near-infrared (NIR) spectrum of one or more of said tablets,
b) comparing said spectrum to a reference NIR spectrum or performing a statistical analysis of said spectrum to determine the tablet porosity,
c) optionally adjusting the tabletting parameters during tabletting in order to improve the NIR spectrum or porosity of the tablets, and
d) selecting a subgroup of tablets with a NIR spectrum or porosity within a predetermined range,
wherein said method optionally is an at-line or an in-line NIR method.
